TNF-α -857C>T Genotype is Predictive of Clinical Response after Treatment with Definitive 5-Fluorouracil/cisplatin-based Chemoradiotherapy in Japanese Patients with Esophageal Squamous Cell Carcinoma

Background: Genotypes of tumor necrosis factor alpha (TNF-α) and its surface receptors, TNFRSF1A and TNFRSF1B, have been examined in terms of the progression, metastasis, clinical efficacy, and prognosis of various cancers; however, little is known about their effects on clinical outcome in patients...

Full description

Bibliographic Details
Main Authors: Omatsu, Hideaki, Kuwahara, Akiko, Yamamori, Motohiro, Fujita, Megumi, Okuno, Tatsuya, Miki, Ikuya, Tamura, Takao, Nishiguchi, Kohshi, Okamura, Noboru, Nakamura, Tsutomu, Azuma, Takeshi, Hirano, Takeshi, Ozawa, Koichiro, Hirai, Midori
Format: Online
Language:English
Published: Ivyspring International Publisher 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804799/
Description
Summary:Background: Genotypes of tumor necrosis factor alpha (TNF-α) and its surface receptors, TNFRSF1A and TNFRSF1B, have been examined in terms of the progression, metastasis, clinical efficacy, and prognosis of various cancers; however, little is known about their effects on clinical outcome in patients with esophageal squamous cell carcinoma (ESCC). In this study, TNF-α and TNFRSF1A genotypes were retrospectively evaluated in terms of predicting clinical response, long-term survival, and severe acute toxicities in 46 male Japanese ESCC patients treated with definitive 5-fluorouracil (5-FU)/cisplatin (CDDP)-based chemoradiotherapy (CRT).